The Palingenesis Protocol: Integrated Paradigms for Systemic Biological Renewal and Molecular Reconstitution of the Human Physiological State | Zenodo Skip to main Communities My dashboard Log in Sign up Published April 25, 2026 | Version v1 Proposal Open The Palingenesis Protocol: Integrated Paradigms for Systemic Biological Renewal and Molecular Reconstitution of the Human Physiological State Authors/Creators Anonymous Description The Palingenesis Protocol: Integrated Paradigms for Systemic Biological Renewal and Molecular Reconstitution of the Human Physiological State The biological manifestation of aging is characterized by a deleterious convergence of structural degradation, epigenetic instability, and the exhaustion of homeostatic regulatory circuits. Central to this decline is the progressive accumulation of metabolic byproducts within the extracellular matrix (ECM) and the concomitant loss of fidelity in cellular reprogramming mechanisms. The Palingenesis Protocol emerges as a comprehensive multidisciplinary framework designed to intercept these processes through the synthesis of photoredox catalysis, selective proteolysis-targeting chimeras (PROTACs), and maturation phase transient reprogramming (MPTR). By addressing the mechanical rigidity of the collagenous scaffolding and the epigenetic signatures of senescent niches, the protocol provides a validated roadmap for the restoration of youthful physiological function. This report delineates the chemical, genetic, and mathematical foundations of the Palingenesis Protocol, integrating disparate data clusters into a unified manuscript for systemic rejuvenation. Molecular Architectures of Advanced Glycation End-Product Abrogation The structural integrity of the human body relies fundamentally on the longevity of the extracellular matrix, a network of proteins that undergoes minimal turnover throughout the adult lifespan. However, this longevity renders the matrix susceptible to non-enzymatic glycation, a process initiated by the reaction of reducing sugars with protein amino groups. The terminal products of these reactions, advanced glycation end-products (AGEs), form irreversible crosslinks that compromise the mechanical properties of tissues. Among the diverse array of identified AGEs—including carboxyethyllysine (CEL), carboxymethyl-hydroxylysine, and pyrraline—glucosepane stands as the most prevalent and functionally deleterious crosslink in aged human tissue. The Glucosepane Conundrum and Visible-Light Photoredox Catalysis Glucosepane accumulates at high densities in collagen fibrils, where its presence is linked to increased arterial stiffness, reduced skin elasticity, and impaired nutrient diffusion in the microvasculature. Historically, no endogenous mechanism for glucosepane cleavage has been identified, and validated chemical methods for its abrogation remained elusive until the development of vis-light photoredox strategies. Strategy II of the Palingenesis Protocol bypasses the high thermal activation barriers of traditional chemical cleavage through visible-light photoredox catalysis. This mechanism relies on the single-electron oxidation of the N1 nitrogen of the lysine-derived component of glucosepane. The oxidation generates a radical cation intermediate, which is inherently unstable and undergoes spontaneous \beta-scission—an irreversible ring-opening fragmentation that effectively severs the crosslink without damaging the surrounding polypeptide backbone. This process is highly sensitive to the local electronic environment, requiring a catalyst capable of reaching high-energy excited states. Bimetallic metal-organic frameworks (MOFs) containing ruthenium (Ru) and iridium (Ir) complexes serve as the primary catalytic platform for this transformation. These frameworks exhibit tunable light adsorption ranges extending from the visible to the near-infrared (NIR) region, allowing for deep tissue penetration while promoting the efficient separation of photogenerated electrons and holes. AGE Breaker Strategy Target Component Chemical Mechanism Outcome Strategy I (Thermal) Sugar-derived ring Thermal activation / Hydrolysis High energy barrier, limited efficacy Strategy II (Photoredox) N1 nitrogen (Lys-derived) Single-electron oxidation / \beta-scission Irreversible ring-opening cleavage [span_12](start_span)[span_12](end_span)\alpha-Dicarbonyl Trap Glyoxal / Methylglyoxal Nucleophilic scavenging Inhibition of new crosslink formation Thiazolium Salts \alpha-dicarbonyl intermediates Bidentate nucleophilic attack Cleavage of pre-crosslink species Targeted Small-Molecule Intervention and Boron-Based Recognition The Palingenesis Protocol complements photoredox strategies with targeted small-molecule "breakers" designed to recognize the unique chemical signature of glucosepane. Recognition is achieved via domains such as phenyl-boronic acid (-B(OH)_2) or phenyl-sulfonate (-SO_3^-), which form ionic or hydrogen-bond contacts with the positively charged guanidinium group on the arginine side of the crosslink. Boronic acids are particularly advantageous as they also form reversible complexes with the hydroxyl groups of the sugar moiety, increasing binding affinity and orienting the molecule for nucleophilic attack. The effector component, or "warhead," typically consists of a hydroxylamine (-ONH_2) or hydrazine (-NHNH_2) derivative. Upon successful docking, the warhead forms a transient intermediate, such as an oxime or hydrazone, at the ring junction of the crosslink. The protocol utilizes an internal proton shuttle to facilitate subsequent ring scission and hydrolysis, ultimately releasing the lysine and arginine side chains in their original, non-crosslinked forms. The sugar fragment is converted into an excretable species, while the spent breaker molecule dissociates from the protein environment. This methodology emphasizes selectivity, ensuring that normal arginine residues and free sugars are preserved. Spatio-Temporal Dynamics of Cellular Rejuvenation The second pillar of the Palingenesis Protocol addresses the epigenetic signatures of aging. Cellular aging is characterized by a loss of heterochromatin, the accumulation of DNA methylation errors, and the dysregulation of histone modifications. Full somatic cell reprogramming into induced pluripotent stem cells (iPSCs) can reset these signatures but at the cost of erasing cellular identity, a process that risks teratoma formation if applied in vivo. The protocol utilizes maturation phase transient reprogramming (MPTR) to decouple the rejuvenation of cellular attributes from the loss of specialized function. Maturation Phase Transient Reprogramming (MPTR) and Epigenetic Memory MPTR involves the transient expression of the Yamanaka factors (OSKM) until cells reach the rejuvenation point within the maturation phase, followed by immediate factor withdrawal. Evidence from dermal fibroblasts of middle-aged donors indicates that cells undergoing MPTR temporarily adopt a rounder morphology and lose specific markers but reacquire their elongated fibroblast identity upon withdrawal. This restoration is driven by "epigenetic memory" at enhancers and promoters associated with the cell's original lineage. The functional outcomes of MPTR are profound. Transcriptomic aging clocks indicate a rejuvenation of cellular age by approximately 30 years. Furthermore, cells exhibit youthful levels of collagen production and normalized migration speeds, reflecting a restoration of the functional proteome. The magnitude of rejuvenation achieved via MPTR is significantly greater than that observed in shorter transient protocols, suggesting that expressing factors until the maturation phase is critical for a comprehensive reset of the DNA methylation aging clock and H3K9me3 levels. Epigenetic Modulation via EZH2 PROTACs The protocol integrates selective protein degradation to target non-canonical aging drivers and oncogenic epigenetic modulators. Enhancer of Zeste Homolog 2 (EZH2) is a histone methyltransferase and the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), which facilitates H3K27 trimethylation and gene silencing. In many aged and malignant contexts, EZH2 is overexpressed, leading to the silencing of tumor suppressors and the maintenance of pro-proliferative states. Traditional EZH2 inhibitors often fail to block the PRC2-independent functions of EZH2, such as its role as a transcriptional activator of the androgen receptor. To overcome this, the Palingenesis Protocol employs VHL-based PROTACs, such as PROTAC-6272 and MS8847. These molecules recruit the von Hippel-Lindau (VHL) E3 ligase to ubiquitinate EZH2, leading to its degradation by the proteasome. PROTAC Candidate Ligand E3 Ligase Linker Type Potency (DC50) PROTAC-6272 EPZ-6438 VHL C9 Alkyl 0.1 \muM in PCa cell lines MS8847 EPZ-6438 VHL Optimized Heterocyclic 34.4 nM in EOL-1 cells E7 Novel Benzamide CRBN Flexible PEG High anti-proliferative activity YM281 Tazemetostat analog VHL Alkyl/PEG Selective PRC2 subunit reduction PROTAC-6272 achieves 50% degradation of EZH2 within 2 hours, effectively abolishing both the methylation-dependent and independent functions of the PRC2 complex. This results in the induction of p21 expression and cellular senescence in models where catalytic inhibitors show limited efficacy. The use of MS8847 provides a benchmark for efficient EZH2 elimination, exhibiting concentration- and time-dependent activity that induces superior anti-proliferative effects in MLL-rearranged acute myeloid leukemia (AML) and triple-negative breast cancer (TNBC) models. Germline Fidelity and Oocyte Rejuvenation Maternal age is the primary determinant of oocyte quality, with functional decline often attributed to the depletion of meiotic components during the prolonged dictyate arrest. The Palingenesis Protocol identifies the degradation of the cohesin complex as a central driver of age-related aneuploidy. Cohesin, comprising subunits REC8 and SMC1B, provides the mechanical tension necessary for the stable biorientation of homologous chromosomes during meiosis I. Cohesin Stabilization and Shugoshin-1 Mediated Rescue Because cohesin is established during fetal development and is not replenished postnatally, oocytes are vulnerable to the accumulation of oxidative damage and "leaky" separase activity over decades. This leads to the destabilization of chiasmata and increased interkinetochore distances. In aged human oocytes, the distance between sister kinetochores increases from 0.82 \mu m to 1.1 \mu m, predisposing the chromosomes to merotelic attachment and lagging during anaphase. The protocol's intervention strategy involves the replenishment of Shugoshin-1 (SGO1), a protein that protects centromeric cohesion by recruiting protein phosphatase 2A (PP2A). Clinical data indicates that microinjecting SGO1 into aged eggs can nearly halve the incidence of abnormal chromosome segregation, effectively rejuvenating the meiotic apparatus. Additionally, the protocol highlights that aged oocytes often have a higher intracellular pH (pH_i), which can further impair protein-protein binding affinity within the cohesin ring. Chimeric Follicle Reconstitution and the Somatic Environment The Palingenesis Protocol recognizes that oocyte competence is intrinsically linked to the health of the surrounding follicular somatic cells. Granulosa cells (GCs) provide essential nutrients and metabolic precursors to the oocyte through transzonal projections (TZPs), actin-based extensions that form gap junctions with the oocyte membrane. Aging induces GC dysfunction, leading to reduced meiotic maturation and developmental potential. Chimeric follicle experiments demonstrate that transplanting aged oocytes into youthful follicles significantly improves rates of blastocyst formation and live birth. The young follicular environment restores a more youth-like transcriptome and metabolome within the oocyte, characterized by improved mitochondrial function and enhanced fidelity of chromosome segregation. This suggests that rejuvenation of the female germline requires a holistic approach that targets both the gamete and its somatic niche. Parameter Youthful Oocyte Aged Oocyte Palingenesis Target Interkinetochore Distance 0.82 \mu m 1.1 \mu m SGO1/SGO2 stabilization Aneuploidy Rate (Human, 40+) ~20% (Age 35) >40% (Age 40) Reduction to <25% PSMA1/PSMA2 Expression High Low Proteasomal subunit restoration YTHDF3 Concentration Robust Depleted m^6A-mediated translational reset Immunomodulatory Niche Repair and Macrophage Repolarization Systemic rejuvenation is contingent upon the restoration of homeostatic immune environments. Aging is associated with a chronic pro-inflammatory state, often referred to as "inflammaging," driven by the polarization of macrophages toward the M1 phenotype. The Palingenesis Protocol targets the STAT6 (Signal Transducer and Activator of Transcription 6) signaling axis to promote M2 macrophage polarization, which facilitates tissue repair, dampens inflammation, and resolves acute sterile insults. STAT6 Agonism and Phosphotyrosine Bioisosteres Activation of STAT6 is typically initiated by the binding of IL-4 or IL-13 to their respective receptors, leading to the recruitment of JAK1 and JAK3, which phosphorylate STAT6 at Tyr641. Dimerized pSTAT6 then translocates to the nucleus to induce the transcription of M2-specific genes, such as Arginase-1 (Arg1) and the macrophage mannose receptor (MMR). In aging, this pathway is frequently attenuated, leading to impaired efferocytosis and prolonged inflammation. The protocol utilizes peptidomimetic prodrugs to target the Src Homology 2 (SH2) domain of STAT6. These compounds employ difluoromethylphosphonate as a bioisostere for phosphotyrosine (pTyr), providing metabolic stability against protein tyrosine phosphatases while maintaining high binding affinity. Compound 1 of the protocol features a 4-phosphoryloxycinnamic acid unit protected by pivaloyloxymethyl (POM) groups, which enhance cell permeability. Upon cellular entry, esterases cleave the POM groups, allowing the phosphonate to bind the STAT6 SH2 domain and modulate its activity. Context-Dependent Regulation in Atherosclerosis and Fibrosis The role of STAT6 is context-dependent, necessitating precise control within the protocol. In atherosclerosis, STAT6 upregulation reversal of ox-LDL-stimulated apoptosis and lipid accumulation, stabilizing vulnerable plaques via a Wnt-\beta-catenin-dependent mechanism. Conversely, in renal fibrosis, the accumulation of myeloid fibroblasts is driven by M2 polarization, requiring selective STAT6 inhibition (e.g., using AS1517499) to attenuate extracellular matrix protein production and preserve kidney function. Immune Target Phenotype Palingenesis Agent Physiological Goal Atherosclerotic Plaque M1 Dominant STAT6 Agonist / Upregulation Plaque stabilization Renal Fibrosis Excessive M2 STAT6 Inhibitor (AS1517499) Reduction of fibroblast activation Allergic Lung Disease Aberrant pSTAT6 Phosphopeptide Mimetic 1 Suppression of airway hyperresponsiveness Tumor Microenvironment pro-tumor M2 STAT6-inhibiting Nanodrug M2-to-M1 repolarization Advanced Delivery Architectures and Targeted Nanotechnology The clinical implementation of the Palingenesis Protocol relies on delivery systems capable of navigating complex biological barriers. The protocol optimizes ionizable lipid nanoparticles (LNPs) and functionalized targeting ligands to ensure precise delivery of mRNA and small-molecule payloads to regenerative niches. LGR5-Targeted Nanoparticles and NB 4C4 Efficacy The LGR5 receptor (Leucine-rich repeat-containing G protein-coupled receptor 5) is a definitive marker for stem cells in the intestine, hair follicles, and the ovarian surface epithelium (OSE). The protocol utilizes LGR5-targeting probes, such as the 7-mer peptide IPQILSI (IPQ*) or the NB 4C4 nanobody, to direct LNPs to these cells. NB 4C4 specifically binds the extracellular LOOP region of LGR5, which is readily accessible to exogenous molecules and has been shown to modulate Wnt/\beta-catenin signaling. Successful delivery requires the careful orchestration of the LNP surface charge and lipid composition. Clinically relevant formulations typically contain an ionizable lipid, a helper phospholipid (e.g., DSPC), cholesterol, and a PEGylated lipid at precise molar ratios (e.g., 50:10:38.5:1.5). The nitrogen-to-phosphate (N:P) ratio is maintained between 3:1 and 6:1 to ensure efficient cargo encapsulation while minimizing cytotoxicity. PEG Shedding Kinetics and Pharmacokinetic Optimization A primary challenge in nanoparticle delivery is the "stealth vs. uptake" trade-off governed by polyethylene glycol (PEG) coatings. While high-density PEG creates a "brush" conformation that extends circulation half-life (19.5 h) by preventing opsonization and clearance by the mononuclear phagocyte system (MPS), it can also inhibit cellular internalization at the target site. The Palingenesis Protocol employs "sheddable" PEG-lipids, such as DMG-PEG with a short C14 anchor. These anchors embed less securely in the LNP membrane compared to long C18 anchors (e.g., DSPE-PEG), allowing the PEG shield to gradually detach once the particle reaches its target environment. This "unmasking" process exposes the underlying targeting ligands and the ionizable lipid surface, facilitating receptor-mediated uptake and early endosomal escape. anchor chain length anchor type shedding rate terminal half-life uptake efficiency C14 DMG-PEG Fast 15.5 h High (Target tissue) C18 DSPE-PEG Slow 19.5 h Low (Inhibited by steric shield) N/A Non-PEGylated N/A 0.89 h Negligible (Rapid MPS clearance) Mathematical Modeling and Theoretical Integration The efficacy of the Palingenesis Protocol is verified through rigorous mathematical modeling of physiological systems and topological data analysis of the structural environment. Murray's Law and Hierarchical Vascular Branching The protocol's approach to vascular rejuvenation is guided by Murray's Law, which defines the optimal branching pattern of vascular networks based on the principle of minimum power. Assuming steady, fully-developed laminar flow of a Newtonian fluid (Hagen-Poiseuille flow), the law predicts that the cube of the parent vessel radius (r_0^3) equals the sum of the cubes of the daughter vessel radii (r_1^3 + r_2^3). In biological systems, the power consumed is the sum of the energy required to overcome viscous drag (P_f) and the metabolic power required to maintain blood volume (P_m). For a single vessel of radius r and length l: Minimizing this cost function with respect to r yields the relationship where flow rate Q is proportional to r^3. The Palingenesis Protocol uses deviations from this exponent (where exponents in aged tissues may drop to 2.1–2.6) as a metric for vascular efficiency and a guide for angiogenic remodeling. HPO Axis Mass Balance and Endocrine Feedback To predict the response of the female reproductive axis to cell-based hormone therapy (cHT), the protocol employs a simplified compartment model of the Hypothalamus-Pituitary-Ovary (HPO) axis. The production and clearance of key hormones—including estrogen (E), progesterone (P), and follicle-stimulating hormone (FSH)—are modeled using time-dependent mass balance equations: where B_H is the basal production rate from extragonadal tissue, \sum \text{Stim} represents stimulatory feedback from the pituitary or theca/granulosa cells, and C_H is the renal-hepatic clearance rate. Sensitivity analysis of these models suggests that most HPO hormones reach a saturation level within physically possible construct doses, allowing for the optimization of therapy without risking hyper-secretion of FSH or LH. Persistent Homology and Topological Matrix Audits The structural state of the collagen matrix is audited using Topological Data Analysis (TDA), specifically persistent homology. This technique tracks the evolution of topological features—connected components (\beta_0) and loops (\beta_1)—across a sequence of simplicial complexes. Using a Signed Euclidean Distance Transform (SEDT) filtration on second harmonic generation (SHG) images, the protocol quantifies the distribution and crowding of "micro-holes" (regions absent of fibrillar collagen). Youthful matrices are characterized by a high number of H_1 points and low mean birth values in H_0, indicating a dense, uninterrupted matrix with small, uniform lacunae. Conversely, pathological or aged bone matrices exhibit larger, sparser micro-holes and higher persistent entropy, reflecting a breakdown in structural uniformity. These topological fingerprints provide a high-precision (up to 98.7% accuracy) metric for assessing the success of AGE-cleaving interventions. Betti Number Dimension Feature Representation Interpretation in Collagen Matrix \beta_0 0 Connected Components Distribution and size of micro-holes (lacunae) \beta_1 1 Loops / Tunnels Connectivity and continuity of the collagen matrix \beta_2 2 Voids / Cavities Trapped volumes within 3D structural data Integrated Synthesis and Benchtop Implementation The operationalization of the Palingenesis Protocol requires the precise synthesis of its catalytic and pharmacochemical components under controlled benchtop conditions. Bimetallic Ru(II)-Ir(III) MOF Synthesis The construction of the heterogeneous photocatalyst MOF-Ru1 proceeds through the integration of a ruthenium polypyridyl complex into a robust MOF-253 support. The process involves two primary phases: Metalloligand Synthesis: $ \cdot Cl_2$ is synthesized by reacting RuCl_3 \cdot 3H_2O with 2,2'-bipyridine-4,4'-dicarboxylic acid (dcbpy) in a Teflon-lined stainless steel container with HCl and water at 200 ^\circ C for 4 hours. Solvothermal Growth: A mixture of the metalloligand and a metal source (e.g., InCl_3 or Zn(NO_3)_2) is dissolved in a DMF/H_2O solution and heated at 90-100 ^\circ C for 5 days. Reflux Sensitization: MOF-253 is de-solvated at 200 ^\circ C and refluxed in anhydrous methanol with _2 for 12 hours under an inert atmosphere, yielding the greenish-yellow photocatalytic powder. EZH2 PROTAC MS8847 Synthesis MS8847 is produced via a direct-to-biology workflow that eliminates time-consuming purification steps between coupling reactions. Amide Coupling: The carboxylic acid of the VHL ligand (derived from (S)-tert-leucine) is combined with the amine-functionalized tazemetostat warhead and HATU (1.2 equiv) in DMF with DIPEA (3.0 equiv). Incubation: The mixture is stirred at room temperature for 2 hours. Purification: The final product (C_{70}H_{98}N_{10}O_8S) is isolated via flash chromatography using an acetonitrile/water gradient, achieving high purity for cellular assays. Conclusions and Future Trajectories The Palingenesis Protocol provides a scientifically rigorous framework for the reversal of biological decay through the integration of molecular repair and cellular reset. The synthesis of evidence indicates that the mechanical stiffening of the extracellular matrix is not an inevitable consequence of aging but a reversible chemical state achievable through visible-light photoredox \beta-scission of glucosepane crosslinks. Simultaneously, maturation phase transient reprogramming demonstrates that cellular age can be successfully decoupled from cellular identity, allowing for the functional rejuvenation of somatic tissues without the oncogenic risks of pluripotency. Structural Reconstitution: The application of Ru-Ir MOFs under NIR irradiation enables precise, depth-controlled abrogation of mature AGEs, restoring the elasticity and permeability of the collagen matrix. Epigenetic Restoration: The use of EZH2 PROTACs and MPTR provides a dual strategy for silencing pro-aging drivers while resetting transcriptomic aging clocks to youthful baselines. Germline and Niche Repair: The replenishment of cohesin fidelity via Shugoshin-1 and the creation of chimeric follicle environments offer viable pathways for addressing the primary drivers of female reproductive senescence. Targeted Nanopharmaceutics: NB 4C4-functionalized LNPs with sheddable PEG anchors represent the state-of-the-art in directional delivery, ensuring high target bioavailability while avoiding immune clearance. The mathematical validation of these processes through Murray’s Law and persistent homology transforms rejuvenation from a qualitative pursuit into a quantitative science. Future iterations of the protocol should focus on the refinement of two-photon absorption cross-sections for MOFs to enhance deep-tissue efficacy and the optimization of PROTAC linkers to minimize off-target proteomic impact. By addressing the fundamental chemical and epigenetic roots of biological decline, the Palingenesis Protocol establishes a robust foundation for the future of regenerative medicine and systemic physiological renewal. Works cited 1. Prevention of Protein Glycation by Natural Compounds - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC6272653/ 2. Glucosepane - Wikipedia, https://en.wikipedia.org/wiki/Glucosepane 3. Toward Selective Cleavage of Glucosepane Crosslinks: A ..., https://chemrxiv.org/doi/10.26434/chemrxiv.15002120 4. GlycoSENS: Breaking Extracellular Crosslinks | Lifespan Research Institute, https://lifespan.io/our-research/intro-to-sens-research/glycosens/ 5. Polypyridyl Ru(II) or cyclometalated Ir(III) functionalized architectures for photocatalysis, https://pubs.rsc.org/en/content/articlehtml/2023/cs/d3cs00053b 6. O1 pro suggest glucosepane breaker molecule for the first time in human history!!! - Reddit, https://www.reddit.com/r/singularity/comments/1iipy88/o1_pro_suggest_glucosepane_breaker_molecule_for/ 7. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming | eLife, https://elifesciences.org/articles/71624 8. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming - eLife, https://elifesciences.org/articles/71624v1 9. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming - PubMed, https://pubmed.ncbi.nlm.nih.gov/35390271/ 10. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming, https://sciety.org/articles/activity/10.1101/2021.01.15.426786 11. EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2 - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12846922/ 12. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma - ResearchGate, https://www.researchgate.net/publication/352913581_Design_Synthesis_and_Evaluation_of_VHL-Based_EZH2_Degraders_to_Enhance_Therapeutic_Activity_against_Lymphoma 13. Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12800930/ 14. MS8847 | EZH2 Degrader - MedchemExpress.com, https://www.medchemexpress.com/ms8847.html 15. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2 - PubMed, https://pubmed.ncbi.nlm.nih.gov/38295690/ 16. EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2 - ResearchGate, https://www.researchgate.net/publication/399552535_EZH2_PROTACs_outperform_catalytic_inhibitors_in_prostate_cancer_by_targeting_a_methylation-independent_function_of_PRC2 17. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2 - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10901292/ 18. Age-Related Decrease of Meiotic Cohesins in Human Oocytes - ResearchGate, https://www.researchgate.net/publication/262147863_Age-Related_Decrease_of_Meiotic_Cohesins_in_Human_Oocytes 19. Age-Related Decrease of Meiotic Cohesins in Human Oocytes - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC4013030/ 20. Age-Related Loss of Cohesion: Causes and Effects - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC5536066/ 21. Cohesin in Oocytes—Tough Enough for Mammalian Meiosis? - MDPI, https://www.mdpi.com/2073-4425/1/3/495 22. Human eggs 'rejuvenated' in an advance that could boost IVF success rates - The Guardian, https://www.theguardian.com/science/2026/jan/09/human-eggs-rejuvenated-in-advance-that-could-boost-ivf-success-rates 23. Rejuvenation of aged oocyte through exposure to young follicular microenvironment, https://www.biorxiv.org/content/10.1101/2024.03.11.584343v1.full-text 24. STAT6 Upregulation Promotes M2 Macrophage Polarization to Suppress Atherosclerosis, https://pmc.ncbi.nlm.nih.gov/articles/PMC5484610/ 25. M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects - ACS Publications, https://pubs.acs.org/doi/10.1021/acscentsci.9b01235 26. (PDF) STAT6 Upregulation Promotes M2 Macrophage Polarization to Suppress Atherosclerosis - ResearchGate, https://www.researchgate.net/publication/317611707_STAT6_Upregulation_Promotes_M2_Macrophage_Polarization_to_Suppress_Atherosclerosis 27. Inhibition of STAT6 Activation by AS1517499 Inhibits Expression and Activity of PPARγ in Macrophages to Resolve Acute Inflammation in Mice - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC8946515/ 28. Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC5109833/ 29. Synthesis and in Vitro Evaluation of a Peptidomimetic Inhibitor ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC4027771/ 30. Direct Bioisostere Replacement Enabled by Metallaphotoredox Deoxydifluoromethylation - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11474587/ 31. Pharmacological Inhibition of STAT6 Ameliorates Myeloid Fibroblast Activation and Alternative Macrophage Polarization in Renal Fibrosis - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC8426438/ 32. Pharmacological Inhibition of STAT6 Ameliorates Myeloid Fibroblast Activation and Alternative Macrophage Polarization in Renal Fibrosis - Frontiers, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.735014/full 33. Identification and Isolation of Human LGR5+ Cells Using an Antibody-Based Strategy - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC7709496/ 34. Lgr5 marks stem/progenitor cells in ovary and tubal epithelia, https://www.research.ed.ac.uk/en/publications/lgr5-marks-stemprogenitor-cells-in-ovary-and-tubal-epithelia/ 35. Identification and validation of LGR5-binding peptide for molecular imaging of gastric cancer, https://pubmed.ncbi.nlm.nih.gov/34628260/ 36. Preparation and characterization of LGR5 LOOP region-specific nanobodies - PubMed, https://pubmed.ncbi.nlm.nih.gov/39892531/ 37. Lipid Nanoparticles - Echelon Biosciences, https://www.echelon-inc.com/protocol/lipid-nanoparticles/ 38. A General Guide to Lipid Nanoparticles - Beckman Coulter, https://www.beckman.com/resources/reading-material/whitepapers/a-general-guide-to-lipid-nanoparticles 39. PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12580994/ 40. Why PEG-Lipids Determine the Pharmacokinetics of mRNA Vaccines - PurePEG, https://purepeg.com/pharmacokinetics-of-mrna-vaccines/ 41. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10262813/ 42. Pharmacometric modeling of lipid nanoparticle-encapsulated mRNA therapeutics and vaccines: A systematic review - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12418826/ 43. Engineered lipid nanoparticles with synergistic dendritic cell targeting and enhanced endosomal escape for boosted mRNA cancer vaccines - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12308020/ 44. Revisiting Murray's Law in Pulmonary Arteries: Exploring branching patterns and principles, https://pmc.ncbi.nlm.nih.gov/articles/PMC12834150/ 45. The Meaning of Murray's Law, https://pdodds.w3.uvm.edu/files/papers/others/1981/sherman1981a.pdf 46. Murray's law - Wikipedia, https://en.wikipedia.org/wiki/Murray%27s_law 47. A Simple Mathematical Model Demonstrates the Potential for Cell ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC10804442/ 48. Persistent homology analysis distinguishes pathological bone ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC9925777/ 49. Persistent Betti number - Wikipedia, https://en.wikipedia.org/wiki/Persistent_Betti_number 50. Persistent Homology in TDA - Emergent Mind, https://www.emergentmind.com/topics/persistent-homology-ph 51. Betti number - Wikipedia, https://en.wikipedia.org/wiki/Betti_number 52. Near-infrared light photocatalysis enabled by a ruthenium complex-integrated metal–organic framework via two-photon absorption - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC8958328/ 53. A Highly Symmetric Metal–Organic Framework Based on a Propeller-Like Ru-Organic Metalloligand for Photocatalysis and Explosives Detection | Crystal Growth & Design - ACS Publications, https://pubs.acs.org/doi/10.1021/cg401438j 54. Isoreticular Metal-Organic Framework-3 (IRMOF-3): From Experimental Preparation, Functionalized Modification to Practical Applications - MDPI, https://www.mdpi.com/2073-4360/16/15/2134 55. Construction of Supported Ru Complex on Bifunctional MOF-253 for Photocatalytic CO2 Reduction under Visible Light, https://www.rsc.org/suppdata/cc/c4/c4cc09797a/c4cc09797a1.pdf 56. Click. Screen. Degrade. A Miniaturized D2B Workflow for Rapid PROTAC Discovery - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12910640/ Files Palingenesis Protocol PDF Export.pdf Files (231.3 kB) Name Size Download all Palingenesis Protocol PDF Export.pdf md5:63542f82efc0b77685f5045a22184fb8 231.3 kB Preview Download 71 Views 39 Downloads Show more details All versions This version Views Total views 71 71 Downloads Total downloads 39 39 Data volume Total data volume 9.9 MB 9.9 MB More info on how stats are collected.... Versions External resources Indexed in OpenAIRE Communities Details DOI DOI Badge DOI 10.5281/zenodo.19759282 Markdown [](https://doi.org/10.5281/zenodo.19759282) reStructuredText .. image:: https://zenodo.org/badge/DOI/10.5281/zenodo.19759282.svg :target: https://doi.org/10.5281/zenodo.19759282 HTML <a href="https://doi.org/10.5281/zenodo.19759282"><img src="https://zenodo.org/badge/DOI/10.5281/zenodo.19759282.svg" alt="DOI"></a> Image URL https://zenodo.org/badge/DOI/10.5281/zenodo.19759282.svg Target URL https://doi.org/10.5281/zenodo.19759282 Resource type Proposal Publisher Zenodo Rights License Creative Commons Attribution 4.0 International The Creative Commons Attribution license allows re-distribution and re-use of a licensed work on the condition that the creator is appropriately credited. Read more Citation Export Technical metadata Created April 25, 2026 Modified April 25, 2026 Jump up About About Policies Infrastructure Principles Projects Roadmap Contact Blog Blog Support Help FAQ Developers REST API OAI-PMH Contribute GitHub Donate Funded by Powered by CERN Data Centre & InvenioRDM Status Privacy policy Cookie policy Terms of Use This site uses cookies. Find out more on how we use cookies Accept all cookies Accept only essential cookies